Viral SARS-CoV-2 Rebound Rates in Linked Commercial Pharmacy-Based Testing and Health Care Claims.
Scott P KellyLisa M McEwenMagnus IsakssonSarah MurphySimon WhiteMatthew E LevyJohn T McCroneGeraint LevanSharad SanthanamMary Lynn BanieckiCandace BramsonHeather RubinoVicky HendrickHolly SoaresJennifer HammondShishi LuoPublished in: Open forum infectious diseases (2024)
Our findings suggest viral RNA rebound is rare (< 5%), with rates that were consistent with those from the EPIC-HR trial (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients). Most occurrences of viral RNA rebound were associated with low viral RNA levels, and viral RNA rebound progression to severe disease was not observed.